Nitric oxide (NO), synthesized by endothelial nitric oxide synthase (eNOS), exerts control over vascular function via two distinct mechanisms, the activation of soluble guanylate cyclase (sGC)/cGMP-dependent signaling or through S-nitrosylation of proteins with reactive thiols (S-nitrosylation). Previous studies in cultured endothelial cells revealed that eNOS targeted to the plasma membrane (PM) releases greater amounts of NO compared with Golgi tethered eNOS. However, the significance of eNOS localization to sGC-dependent or -independent signaling is not known. Here we show that PM-targeted eNOS, when expressed in human aortic endothelial cells (HAEC) and isolated blood vessels, increases sGC/cGMP signaling to a greater extent than Golgi-localized eNOS. The ability of local NO production to influence sGC-independent mechanisms was also tested by monitoring the secretion of Von Willebrand factor (vWF), which is tonically inhibited by the Snitrosylation of N-ethylmaleimide sensitive factor (NSF). In eNOS "knockdown" HAECs, vWF secretion was attenuated to a greater degree by PM eNOS compared with a Golgi-restricted eNOS. Moreover, the PM-targeted eNOS induced greater S-nitrosylation of NSF vs. Golgi eNOS. To distinguish between the amount of NO generated and the intracellular location of synthesis, we expressed Golgi and PM-targeted calcium-insensitive forms of eNOS in HAEC. These constructs, which generate equal amounts of NO regardless of location, produced equivalent increases in cGMP in bioassays and equal inhibition of vWF secretion. We conclude that the greater functional effects of PM eNOS are due to the increased amount of NO produced rather than effects derived from the local synthesis of NO. nitric oxide; endothelial nitric oxide synthase; endothelium; nitrosylation; intracellular location; Von Willebrand factor CARDIOVASCULAR DISEASE (CVD) remains the principal cause of death in both developed and developing countries, and almost 800,000 die annually in the United States from CVDs that include atherosclerosis, hypertension, congestive heart failure, and stroke (18). Endothelium-derived nitric oxide (NO) as synthesized by endothelial nitric oxide synthase (eNOS) plays a vital role in maintaining cardiovascular homeostasis and has potent effects on vascular tone, smooth muscle cell proliferation and migration, leukocyte adhesion, and platelet aggregation (9). Numerous studies have shown that eNOS is protective against pathological vascular remodeling, hypertension, and atherosclerosis (25,34,40). Moreover, reduced expression and dysregulation of eNOS, which results in the decreased synthesis of NO and the increased production of superoxide instead of NO, increases the severity of CVD (30, 31). However, the mechanisms by which eNOS affords vascular protection are incompletely understood.Endothelial-derived NO controls vascular function via at least two distinct mechanisms. The first is the well-characterized activation of the soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling ...